Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Thinking of Buying Viatris (VTRS)? Here's What You Need to Know.

Shares of Health Care sector company Viatris moved -1.5% today, and are now trading at a price of $10.39. The Large-Cap stock's daily volume was 5,263,715 compared to its average volume of 11,595,806. The S&P 500 index returned a 0.0% performance.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. The company is based in Canonsburg and has 32,000 full time employees. Its market capitalization is $12,119,218,176. Viatris currently offers its equity investors a dividend that yields 4.5% per year.

7 analysts are following Viatris and have set target prices ranging from $8.0 to $14.0 per share. On average, they have given the company a rating of hold. At today's prices, VTRS is trading -9.04% away from its average analyst target price of $11.43 per share.

Over the last year, VTRS shares have gone down by -9.8%, which represents a difference of -24.2% when compared to the S&P 500. The stock's 52 week high is $13.55 per share and its 52 week low is $6.85. With average free cash flows of $1.95 Billion that have been growing at an average rate of 4.4% over the last 5 years, Viatris declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2024 2,302,900 326,000 1,976,900 -21.64
2023 2,900,000 377,000 2,523,000 -2.7
2022 2,999,000 406,000 2,593,000 1.3
2021 3,016,900 457,200 2,559,700 498.62
2020 670,600 243,000 427,600 -73.12
2019 1,803,700 213,200 1,590,500
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS